BridgeMD
A Phase 1/2 Study of BMS-986525 with and without Nivolumab in Relapsed/Refractory Small Cell Lung Cancer
EU CTIS ID: 2025-524090-16-00
What this study is testing
To test if BMS-986525 alone or in combination with nivolumab is safe and well-tolerated and to determine the recommended dose for further testing up to the highest dose of BMS-986453 that can be given without causing severe side effects in patients with Relapsed and/or Refractory SCLC(R/RSCLC)
- Phase I and Phase II (Integrated)- First administration to humans
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants who have had their SCLC come back after previous treatment (relapsed) or have SCLC that is not responding to current treatment (refractory)
- Participants must have received at least 1 platinum-based chemotherapy regimen.
- In countries where the usual first treatment for SCLC includes a combination of platinum-based chemotherapy and anti-PD-(L)1 therapy, participants must have either tried and not responded to anti-PD-(L)1 therapy, not be able to receive it, or not have access to it.
- Participants must have adequate organ function.
You likely can't join if
- Participants must not have any untreated central nervous system (CNS) involvement of SCLC.
- Participants must not have active, known or suspected autoimmune disease.
- Participants must not have previously received an organ or tissue transplant from another person.
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.